
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6815824/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A cross-sectional analysis of subjects enrolled in the COVID-19 Prevention in Emory Healthcare Personnel (COPE) study. Infection Control and Hospital Epidemiology, 2022, 43, 381-386.	1.8	10
2	Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020. Clinical Infectious Diseases, 2022, 74, 1141-1150.	5.8	33
3	Associations of infection control measures and norovirus outbreak outcomes in healthcare settings: a systematic review and meta-analysis. Expert Review of Anti-Infective Therapy, 2022, 20, 279-290.	4.4	4
4	Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020. Journal of Infectious Diseases, 2022, 225, 396-403.	4.0	8
5	Controlling risk of SARS-CoV-2 infection in essential workers of enclosed food manufacturing facilities. Food Control, 2022, 133, 108632.	5.5	12
6	Decontamination of SARS-CoV-2 from cold-chain food packaging provides no marginal benefit in risk reduction to food workers. Food Control, 2022, 136, 108845.	5.5	19
7	Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study. Infection Control and Hospital Epidemiology, 2022, , 1-8.	1.8	7
8	Post-lockdown changes of age-specific susceptibility and its correlation with adherence to social distancing measures. Scientific Reports, 2022, 12, 4637.	3.3	3
9	The changing epidemiology of SARS-CoV-2. Science, 2022, 375, 1116-1121.	12.6	177
10	Association of secretor status and recent norovirus infection with gut microbiome diversity metrics in a Veterans Affairs population. Open Forum Infectious Diseases, 2022, 9, ofac125.	0.9	0
11	Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults. Journal of Infectious Diseases, 2022, , .	4.0	7
12	How to interpret the total number of SARS-CoV-2 infections. Lancet, The, 2022, 399, 2326-2327.	13.7	1
13	Case fatality risk of diarrhoeal pathogens: a systematic review and meta-analysis. International Journal of Epidemiology, 2022, 51, 1469-1480.	1.9	8
14	Understanding Variation in Rotavirus Vaccine Effectiveness Estimates in the United States: The Role of Rotavirus Activity and Diagnostic Misclassification. Epidemiology, 2022, Publish Ahead of Print, .	2.7	1
15	Declining COVID-19 case-fatality in Georgia, USA, March 2020 to March 2021: a sign of real improvement or a broadening epidemic?. Annals of Epidemiology, 2022, , .	1.9	0
16	The hiatus of the handshake. Science, 2022, 377, 33-34.	12.6	1
17	Nationally representative social contact patterns among U.S. adults, August 2020-April 2021. Epidemics, 2022, 40, 100605.	3.0	12
18	Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates. Nature Medicine, 2021, 27, 4-5.	30.7	34

#	Article	IF	CITATIONS
19	Meteorological factors and childhood diarrhea in Peru, 2005–2015: a time series analysis of historic associations, with implications for climate change. Environmental Health, 2021, 20, 22.	4.0	10
20	Impact of Nonpharmaceutical Interventions for Severe Acute Respiratory Syndrome Coronavirus 2 on Norovirus Outbreaks: An Analysis of Outbreaks Reported By 9 US States. Journal of Infectious Diseases, 2021, 224, 9-13.	4.0	47
21	Immunologic and Epidemiologic Drivers of Norovirus Transmission in Daycare and School Outbreaks. Epidemiology, 2021, 32, 351-359.	2.7	9
22	Risk Factors Associated With SARS-CoV-2 Seropositivity Among US Health Care Personnel. JAMA Network Open, 2021, 4, e211283.	5.9	112
23	A modeling study to inform screening and testing interventions for the control of SARS-CoV-2 on university campuses. Scientific Reports, 2021, 11, 5900.	3.3	27
24	Risk for Fomite-Mediated Transmission of SARS-CoV-2 in Child Daycares, Schools, Nursing Homes, and Offices. Emerging Infectious Diseases, 2021, 27, 1229-1231.	4.3	45
25	Cost-effectiveness of pediatric norovirus vaccination in daycare settings. Vaccine, 2021, 39, 2133-2145.	3.8	4
26	Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies. Epidemiology, 2021, 32, 518-524.	2.7	69
27	Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines. Epidemiology, 2021, 32, 508-517.	2.7	84
28	Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study. Lancet Infectious Diseases, The, 2021, 21, 731-740.	9.1	14
29	Quantification of Occupational and Community Risk Factors for SARS-CoV-2 Seropositivity Among Health Care Workers in a Large U.S. Health Care System. Annals of Internal Medicine, 2021, 174, 649-654.	3.9	77
30	Clobal diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection. Vaccine, 2021, 39, 4391-4398.	3.8	12
31	Countyâ€Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005â€2017. Hepatology, 2021, 74, 582-590.	7.3	7
32	SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California. Open Forum Infectious Diseases, 2021, 8, ofab379.	0.9	20
33	Using viral load to model disease dynamics. Science, 2021, 373, 280-281.	12.6	2
34	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. ELife, 2021, 10, .	6.0	50
35	A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children. Clinical Infectious Diseases, 2021, 73, 1759-1767.	5.8	10
36	Describing the changing relationship between opioid prescribing rates and overdose mortality: A novel county-level metric. Drug and Alcohol Dependence, 2021, 225, 108761.	3.2	2

#	Article	IF	CITATIONS
37	Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review and Meta-analysis. Pediatric Infectious Disease Journal, 2021, 40, 1135-1143.	2.0	15
38	Trajectory of COVID-19 Vaccine Hesitancy Over Time and Association of Initial Vaccine Hesitancy With Subsequent Vaccination. JAMA Network Open, 2021, 4, e2126882.	5.9	71
39	Social contact patterns among employees in 3 U.S. companies during early phases of the COVID-19 pandemic, April to June 2020. Epidemics, 2021, 36, 100481.	3.0	17
40	Association of enteropathogen detection with diarrhoea by age and high versus low child mortality settings: a systematic review and meta-analysis. The Lancet Global Health, 2021, 9, e1402-e1410.	6.3	17
41	Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Georgia, USA, February 1–July 13, 2020. Emerging Infectious Diseases, 2021, 27, 2578-2587.	4.3	7
42	A framework for monitoring population immunity to SARS-CoV-2. Annals of Epidemiology, 2021, 63, 75-78.	1.9	19
43	Dynamic network strategies for SARS-CoV-2 control on a cruise ship. Epidemics, 2021, 37, 100488.	3.0	9
44	Hospital-based Surveillance for Pediatric Norovirus Gastroenteritis in Bangladesh, 2012–2016. Pediatric Infectious Disease Journal, 2021, 40, 215-219.	2.0	4
45	1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). Open Forum Infectious Diseases, 2021, 8, S752-S753.	0.9	0
46	1334. Outcomes Among Influenza and SARS-CoV-2 Infection in Hospitalized Adults Age ≥ 50 Years and with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). Open Forum Infectious Diseases, 2021, 8, S755-S755.	0.9	0
47	1340. The Burden of Influenza and Rhinovirus Among Hospitalized Adults Post the COVID-19 Pandemic. Open Forum Infectious Diseases, 2021, 8, S757-S758.	0.9	1
48	1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis. Open Forum Infectious Diseases, 2021, 8, S676-S676.	0.9	0
49	Modeling serological testing to inform relaxation of social distancing for COVID-19 control. Nature Communications, 2021, 12, 7063.	12.8	11
50	Evidence for Household Transmission of Rotavirus in the United States, 2011–2016. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 181-187.	1.3	13
51	Trends in Incidence of Norovirus-associated Acute Gastroenteritis in 4 Veterans Affairs Medical Center Populations in the United States, 2011–2015. Clinical Infectious Diseases, 2020, 70, 40-48.	5.8	11
52	Understanding the Importance of Contact Heterogeneity and Variable Infectiousness in the Dynamics of a Large Norovirus Outbreak. Clinical Infectious Diseases, 2020, 70, 493-500.	5.8	4
53	Effect of Concomitant Antibiotic and Vaccine Administration on Serologic Responses to Rotavirus Vaccine. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 479-482.	1.3	2
54	Early Evidence of Inactivated Enterovirus 71 Vaccine Impact Against Hand, Foot, and Mouth Disease in a Major Center of Ongoing Transmission in China, 2011–2018: A Longitudinal Surveillance Study. Clinical Infectious Diseases, 2020, 71, 3088-3095.	5.8	33

#	Article	IF	CITATIONS
55	Factors Associated With Measles Transmission in the United States During the Postelimination Era. JAMA Pediatrics, 2020, 174, 56.	6.2	25
56	Population-Level Human Secretor Status Is Associated With Genogroup 2 Type 4 Norovirus Predominance. Journal of Infectious Diseases, 2020, 221, 1855-1863.	4.0	3
57	Duration and Density of Fecal Rotavirus Shedding in Vaccinated Malawian Children With Rotavirus Gastroenteritis. Journal of Infectious Diseases, 2020, 222, 2035-2040.	4.0	13
58	Characterizing Norovirus Transmission from Outbreak Data, United States. Emerging Infectious Diseases, 2020, 26, 1818-1825.	4.3	12
59	Impact of Rotavirus Vaccination Varies by Level of Access to Piped Water and Sewerage: An Analysis of Childhood Clinic Visits for Diarrhea in Peru, 2005–2015. Pediatric Infectious Disease Journal, 2020, 39, 756-762.	2.0	6
60	Characterizing superspreading events and age-specific infectiousness of SARS-CoV-2 transmission in Georgia, USA. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22430-22435.	7.1	178
61	Protocol for a national probability survey using home specimen collection methods to assess prevalence and incidence of SARS-CoV-2 infection and antibody response. Annals of Epidemiology, 2020, 49, 50-60.	1.9	36
62	Social Mixing and Clinical Features Linked With Transmission in a Network of Extensively Drug-resistant Tuberculosis Cases in KwaZulu-Natal, South Africa. Clinical Infectious Diseases, 2020, 70, 2396-2402.	5.8	4
63	Modeling of rotavirus transmission dynamics and impact of vaccination in Ghana. Vaccine, 2020, 38, 4820-4828.	3.8	10
64	Quantifying the roles of vomiting, diarrhea, and residents vs. staff in norovirus transmission in U.S. nursing home outbreaks. PLoS Computational Biology, 2020, 16, e1007271.	3.2	4
65	A spatial hierarchical model for integrating and bias-correcting data from passive and active disease surveillance systems. Spatial and Spatio-temporal Epidemiology, 2020, 35, 100341.	1.7	4
66	Postvaccination Serum Antirotavirus Immunoglobulin A as a Correlate of Protection Against Rotavirus Gastroenteritis Across Settings. Journal of Infectious Diseases, 2020, 222, 309-318.	4.0	21
67	Surveillance data confirm multiyear predictions of rotavirus dynamics in New York City. Science Advances, 2020, 6, eaax0586.	10.3	7
68	Disease burden and seasonal impact of improving rotavirus vaccine coverage in the United States: AÂmodeling study. PLoS ONE, 2020, 15, e0228942.	2.5	5
69	Modeling Missing Cases and Transmission Links in Networks of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. American Journal of Epidemiology, 2020, 189, 735-745.	3.4	7
70	Wading Into the Morass: Natural Immunity to Enteropathogens. Journal of Infectious Diseases, 2020, 222, 1764-1767.	4.0	1
71	The DIOS framework for optimizing infectious disease surveillance: Numerical methods for simulation and multi-objective optimization of surveillance network architectures. PLoS Computational Biology, 2020, 16, e1008477.	3.2	3
72	506. Variation in Occupational Activities and Infection Prevention Practices in Healthcare Personnel Based on Exposure to COVID-19 Units. Open Forum Infectious Diseases, 2020, 7, S319-S319.	0.9	0

#	Article	IF	CITATIONS
73	Title is missing!. , 2020, 16, e1007271.		0
74	Title is missing!. , 2020, 16, e1007271.		0
75	Title is missing!. , 2020, 16, e1007271.		0
76	Title is missing!. , 2020, 16, e1007271.		0
77	Title is missing!. , 2020, 16, e1007271.		0
78	Title is missing!. , 2020, 16, e1007271.		0
79	Title is missing!. , 2020, 15, e0228942.		0
80	Title is missing!. , 2020, 15, e0228942.		0
81	Title is missing!. , 2020, 15, e0228942.		0
82	Title is missing!. , 2020, 15, e0228942.		0
83	Longer-term Direct and Indirect Effects of Infant Rotavirus Vaccination Across All Ages in the United States in 2000–2013: Analysis of a Large Hospital Discharge Data Set. Clinical Infectious Diseases, 2019, 68, 976-983.	5.8	28
84	Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi. Science Translational Medicine, 2019, 11, .	12.4	25
85	Heterogeneous susceptibility to rotavirus infection and gastroenteritis in two birth cohort studies: Parameter estimation and epidemiological implications. PLoS Computational Biology, 2019, 15, e1007014.	3.2	4
86	Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. The Lancet Global Health, 2019, 7, e1541-e1552.	6.3	46
87	Changes in micronutrient and inflammation serum biomarker concentrations after a norovirus human challenge. American Journal of Clinical Nutrition, 2019, 110, 1456-1464.	4.7	29
88	Infrequent Transmission of Monovalent Human Rotavirus Vaccine Virus to Household Contacts of Vaccinated Infants in Malawi. Journal of Infectious Diseases, 2019, 219, 1730-1734.	4.0	8
89	Effect of propensity of seeking medical care on the bias of the estimated effectiveness of rotavirus vaccines from studies using a test-negative case-control design. Vaccine, 2019, 37, 3229-3233.	3.8	0
90	Effects of the rotavirus vaccine program across age groups in the United States: analysis of national claims data, 2001–2016. BMC Infectious Diseases, 2019, 19, 186.	2.9	32

#	Article	IF	CITATIONS
91	Active Surveillance for Norovirus in a US Veterans Affairs Patient Population, Houston, Texas, 2015–2016. Open Forum Infectious Diseases, 2019, 6, ofz115.	0.9	6
92	Incomplete use of global data for aetiological attribution of diarrhoeal disease in the Global Burden of Disease study. Lancet Infectious Diseases, The, 2019, 19, 128.	9.1	11
93	Birth Cohort Studies Assessing Norovirus Infection and Immunity in Young Children: A Review. Clinical Infectious Diseases, 2019, 69, 357-365.	5.8	43
94	2314. Burden of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). Open Forum Infectious Diseases, 2019, 6, S793-S794.	0.9	0
95	Antirotavirus IgA seroconversion rates in children who receive concomitant oral poliovirus vaccine: A secondary, pooled analysis of Phase II and III trial data from 33 countries. PLoS Medicine, 2019, 16, e1003005.	8.4	11
96	The Population-Level Impacts of Excluding Norovirus-Infected Food Workers From the Workplace: A Mathematical Modeling Study. American Journal of Epidemiology, 2019, 188, 177-187.	3.4	7
97	Global Review of the Age Distribution of Rotavirus Disease in Children Aged <5 Years Before the Introduction of Rotavirus Vaccination. Clinical Infectious Diseases, 2019, 69, 1071-1078.	5.8	38
98	Evaluation of Intussusception after Monovalent Rotavirus Vaccination in Africa. New England Journal of Medicine, 2018, 378, 1521-1528.	27.0	93
99	Rotavirus strain distribution in Ghana pre- and post- rotavirus vaccine introduction. Vaccine, 2018, 36, 7238-7242.	3.8	38
100	Waxing Understanding of Waning Immunity. Journal of Infectious Diseases, 2018, 217, 851-853.	4.0	20
101	Temporal Relationship Between Healthcare-Associated and Nonhealthcare-Associated Norovirus Outbreaks and Google Trends Data in the United States. Infection Control and Hospital Epidemiology, 2018, 39, 355-358.	1.8	9
102	Causes of impaired oral vaccine efficacy in developing countries. Future Microbiology, 2018, 13, 97-118.	2.0	154
103	Rotavirus Vaccines and Health Care Utilization for Diarrhea in US Children, 2001 to 2015. Pediatric Infectious Disease Journal, 2018, 37, 943-948.	2.0	12
104	Timing of Birth as an Emergent Risk Factor for Rotavirus Hospitalization and Vaccine Performance in the United States. American Journal of Epidemiology, 2018, 187, 1745-1751.	3.4	3
105	Use of Internet Search Data to Monitor Rotavirus Vaccine Impact in the United States, United Kingdom, and Mexico. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 56-63.	1.3	12
106	National Estimates of Reductions in Acute Gastroenteritis–Related Hospitalizations and Associated Costs in US Children After Implementation of Rotavirus Vaccines. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 257-260.	1.3	26
107	Evaluating Previous Antibiotic Use as a Risk Factor for Acute Gastroenteritis Among Children in Davidson County, Tennessee, 2014–2015. Journal of the Pediatric Infectious Diseases Society, 2018, 7, e86-e91.	1.3	5
108	A comparison of the test-negative and traditional case-control study designs with respect to the bias of rotavirus vaccine effectiveness. Vaccine, 2018, 36, 5071-5076.	3.8	14

#	Article	IF	CITATIONS
109	Burden of Severe Norovirus Disease in Taiwan, 2003–2013. Clinical Infectious Diseases, 2018, 67, 1373-1378.	5.8	15
110	Annual changes in rotavirus hospitalization rates before and after rotavirus vaccine implementation in the United States. PLoS ONE, 2018, 13, e0191429.	2.5	21
111	Norovirus in Latin America. Pediatric Infectious Disease Journal, 2017, 36, 127-134.	2.0	35
112	Parenteral protein-based rotavirus vaccine. Lancet Infectious Diseases, The, 2017, 17, 786-787.	9.1	7
113	Assessment of the Status of Measles Elimination in the United States, 2001–2014. American Journal of Epidemiology, 2017, 185, 562-569.	3.4	16
114	Naturally Acquired Immunity Against Rotavirus Infection and Gastroenteritis in Children: Paired Reanalyses of Birth Cohort Studies. Journal of Infectious Diseases, 2017, 216, 317-326.	4.0	26
115	Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortality. Vaccine, 2017, 35, 7198-7203.	3.8	25
116	Etiology of Severe Acute Watery Diarrhea in Children in the Global Rotavirus Surveillance Network Using Quantitative Polymerase Chain Reaction. Journal of Infectious Diseases, 2017, 216, 220-227.	4.0	100
117	Incidence of Norovirus-Associated Diarrhea and Vomiting Disease Among Children and Adults in a Community Cohort in the Peruvian Amazon Basin. Clinical Infectious Diseases, 2017, 65, 833-839.	5.8	13
118	The Residual Vaccine-preventable Burden of Rotavirus Disease. Pediatric Infectious Disease Journal, 2017, 36, 780-781.	2.0	2
119	Estimating the Burden of Medically Attended Norovirus Gastroenteritis: Modeling Linked Primary Care and Hospitalization Datasets. Journal of Infectious Diseases, 2017, 216, 957-965.	4.0	28
120	Active Surveillance to Quantify the Burden of Norovirus in a U.S. Veterans Affairs (VA) Patient Population, Houston, 2015–2016. Open Forum Infectious Diseases, 2017, 4, S317-S317.	0.9	0
121	Can Use of Viral Load Improve Norovirus Clinical Diagnosis and Disease Attribution?. Open Forum Infectious Diseases, 2017, 4, ofx131.	0.9	21
122	Estimating the incidence of rotavirus infection in children from India and Malawi from serial anti-rotavirus IgA titres. PLoS ONE, 2017, 12, e0190256.	2.5	9
123	Incidence of Norovirus-Associated Medical Encounters among Active Duty United States Military Personnel and Their Dependents. PLoS ONE, 2016, 11, e0148505.	2.5	13
124	Global Economic Burden of Norovirus Gastroenteritis. PLoS ONE, 2016, 11, e0151219.	2.5	385
125	Strain-Specific Virolysis Patterns of Human Noroviruses in Response to Alcohols. PLoS ONE, 2016, 11, e0157787.	2.5	14
126	Editorial Commentary: Pediatric Norovirus in Developing Countries: A Picture Slowly Comes Into Focus. Clinical Infectious Diseases, 2016, 62, 1218-1220.	5.8	7

#	Article	IF	CITATIONS
127	Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options. Epidemics, 2016, 17, 42-49.	3.0	26
128	Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial. Journal of Infectious Diseases, 2016, 213, 1686-1693.	4.0	44
129	Host Genetic Susceptibility to Enteric Viruses: A Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2016, 62, 11-18.	5.8	99
130	Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh. Clinical Infectious Diseases, 2016, 62, 150-156.	5.8	55
131	The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control. PLoS Medicine, 2016, 13, e1001999.	8.4	305
132	Innate Resistance and Susceptibility to Norovirus Infection. PLoS Pathogens, 2016, 12, e1005385.	4.7	53
133	Transmission of Norovirus Within Households in Quininde, Ecuador. Pediatric Infectious Disease Journal, 2015, 34, 1031-1033.	2.0	16
134	Acute Gastroenteritis Hospitalizations Among US Children Following Implementation of the Rotavirus Vaccine. JAMA - Journal of the American Medical Association, 2015, 313, 2282.	7.4	65
135	Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. Lancet Infectious Diseases, The, 2015, 15, 703-710.	9.1	64
136	Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. Expert Review of Vaccines, 2015, 14, 1241-1253.	4.4	38
137	Noroviruses: epidemiology, immunity and prospects for prevention. Future Microbiology, 2015, 10, 53-67.	2.0	78
138	Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children. Current Opinion in Pediatrics, 2015, 27, 105-109.	2.0	21
139	Norovirus Genotype Profiles Associated with Foodborne Transmission, 1999–2012. Emerging Infectious Diseases, 2015, 21, 592-599.	4.3	136
140	Reduced Rotavirus Vaccine Effectiveness Among Children Born During the Rotavirus Season: A Pooled Analysis of 5 Case-Control Studies From the Americas. Clinical Infectious Diseases, 2015, 60, 1075-1078.	5.8	4
141	Incidence of Medically-Attended Norovirus-Associated Acute Gastroenteritis in Four Veteran's Affairs Medical Center Populations in the United States, 2011-2012. PLoS ONE, 2015, 10, e0126733.	2.5	13
142	Editorial Commentary: In Praise of Birth Cohorts: Norovirus Infection, Disease, and Immunity. Clinical Infectious Diseases, 2014, 58, 492-494.	5.8	20
143	Rotavirus vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 1436-1448.	3.3	77
144	RNA Populations in Immunocompromised Patients as Reservoirs for Novel Norovirus Variants. Journal of Virology, 2014, 88, 14184-14196.	3.4	44

**BENJAMIN A LOPMAN** 

#	Article	IF	CITATIONS
145	Effectiveness and impact of rotavirus vaccines in the United States – 2006–2012. Expert Review of Vaccines, 2014, 13, 365-376.	4.4	88
146	Norovirus in healthcare settings. Current Opinion in Infectious Diseases, 2014, 27, 437-443.	3.1	50
147	Epidemiologic Implications of Asymptomatic Reinfection: A Mathematical Modeling Study of Norovirus. American Journal of Epidemiology, 2014, 179, 507-512.	3.4	70
148	Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2014, 14, 725-730.	9.1	905
149	Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2014, 14, 847-856.	9.1	182
150	Rotavirus Vaccines and Health Care Utilization for Diarrhea in the United States (2007–2011). Pediatrics, 2014, 134, 15-23.	2.1	120
151	Fitting outbreak models to data from many small norovirus outbreaks. Epidemics, 2014, 6, 18-29.	3.0	21
152	Gastroenteritis Hospitalizations in Older Children and Adults in the United States Before and After Implementation of Infant Rotavirus Vaccination. JAMA - Journal of the American Medical Association, 2013, 310, 851.	7.4	80
153	A Systematic Review of Anti-Rotavirus Serum IgA Antibody Titer as a Potential Correlate of Rotavirus Vaccine Efficacy. Journal of Infectious Diseases, 2013, 208, 284-294.	4.0	150
154	Norovirus and Medically Attended Gastroenteritis in U.S. Children. New England Journal of Medicine, 2013, 368, 1121-1130.	27.0	518
155	Clinical characteristics of norovirus-associated deaths: A systematic literature review. American Journal of Infection Control, 2013, 41, 654-657.	2.3	70
156	Detection and molecular characterisation of noroviruses in hospitalised children in Malawi, 1997–2007. Journal of Medical Virology, 2013, 85, 1299-1306.	5.0	38
157	Duration of Immunity to Norovirus Gastroenteritis. Emerging Infectious Diseases, 2013, 19, 1260-1267.	4.3	165
158	Clinical Profile of Children with Norovirus Disease in Rotavirus Vaccine Era. Emerging Infectious Diseases, 2013, 19, 1691-1693.	4.3	33
159	Trends in National Rotavirus Activity Before and After Introduction of Rotavirus Vaccine into the National Immunization Program in the United States, 2000 to 2012. Pediatric Infectious Disease Journal, 2013, 32, 741-744.	2.0	72
160	Global Seasonality of Rotavirus Disease. Pediatric Infectious Disease Journal, 2013, 32, e134-e147.	2.0	148
161	Norovirus Disease in the United States. Emerging Infectious Diseases, 2013, 19, 1198-1205.	4.3	478
162	Emergency Department Visit Data for Rapid Detection and Monitoring of Norovirus Activity, United States. Emerging Infectious Diseases, 2013, 19, 1214-1221.	4.3	25

10

#	Article	IF	CITATIONS
163	Linking Time-Varying Symptomatology and Intensity of Infectiousness to Patterns of Norovirus Transmission. PLoS ONE, 2013, 8, e68413.	2.5	19
164	A Systematic Review and Meta-Analysis of the Global Seasonality of Norovirus. PLoS ONE, 2013, 8, e75922.	2.5	213
165	Comparison of Age-Stratified Seroprevalence of Antibodies against Norovirus GII in India and the United Kingdom. PLoS ONE, 2013, 8, e56239.	2.5	19
166	Household Transmission of Rotavirus in a Community with Rotavirus Vaccination in Quininde, Ecuador. PLoS ONE, 2013, 8, e67763.	2.5	17
167	Potential Intussusception Risk Versus Health Benefits From Rotavirus Vaccination in Latin America. Clinical Infectious Diseases, 2012, 54, 1397-1405.	5.8	32
168	Use of Internet Search Data to Monitor Impact of Rotavirus Vaccination in the United States. Clinical Infectious Diseases, 2012, 54, e115-e118.	5.8	24
169	Norovirus Disease Surveillance Using Google Internet Query Share Data. Clinical Infectious Diseases, 2012, 55, e75-e78.	5.8	45
170	Duration of Protection of Pentavalent Rotavirus Vaccination in Nicaragua. Pediatrics, 2012, 130, e365-e372.	2.1	51
171	Hospitalizations and Mortality Associated With Norovirus Outbreaks in Nursing Homes, 2009-2010. JAMA - Journal of the American Medical Association, 2012, 308, 1668.	7.4	83
172	Severe Outcomes Are Associated With Genogroup 2 Genotype 4 Norovirus Outbreaks: A Systematic Literature Review. Clinical Infectious Diseases, 2012, 55, 189-193.	5.8	147
173	Decline in Gastroenteritis-Related Triage Calls After Rotavirus Vaccine Licensure. Pediatrics, 2012, 130, e872-e878.	2.1	6
174	Environmental transmission of norovirus gastroenteritis. Current Opinion in Virology, 2012, 2, 96-102.	5.4	244
175	Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality. Expert Review of Vaccines, 2012, 11, 211-220.	4.4	33
176	Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011. Current Opinion in Virology, 2012, 2, 434-442.	5.4	48
177	Epidemiology of Foodborne Norovirus Outbreaks, United States, 2001–2008. Emerging Infectious Diseases, 2012, 18, 1566-1573.	4.3	183
178	The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999–2007. Clinical Infectious Diseases, 2012, 55, 216-223.	5.8	258
179	Understanding Reduced Rotavirus Vaccine Efficacy in Low Socio-Economic Settings. PLoS ONE, 2012, 7, e41720.	2.5	115
180	Direct and Indirect Effects of Rotavirus Vaccination: Comparing Predictions from Transmission Dynamic Models. PLoS ONE, 2012, 7, e42320.	2.5	60

#	Article	IF	CITATIONS
181	Reduction in morbidity and mortality from childhood diarrhoeal disease after species A rotavirus vaccine introduction in Latin America : a review. Memorias Do Instituto Oswaldo Cruz, 2011, 106, 907-911.	1.6	50
182	Decline in Diarrhea Mortality and Admissions after Routine Childhood Rotavirus Immunization in Brazil: A Time-Series Analysis. PLoS Medicine, 2011, 8, e1001024.	8.4	202
183	Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States. Pediatric Infectious Disease Journal, 2011, 30, S56-S60.	2.0	140
184	Sustained Decline in Rotavirus Detections in the United States Following the Introduction of Rotavirus Vaccine in 2006. Pediatric Infectious Disease Journal, 2011, 30, S30-S34.	2.0	121
185	Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19353-19358.	7.1	74
186	Rotavirus vaccines. Hum Vaccin, 2011, 7, 1282-1290.	2.4	55
187	Incidence of Acute Gastroenteritis and Role of Norovirus, Georgia, USA, 2004-2005. Emerging Infectious Diseases, 2011, 17, 1381-8.	4.3	124
188	Impact of an Emergent Norovirus Variant in 2009 on Norovirus Outbreak Activity in the United States. Clinical Infectious Diseases, 2011, 53, 568-571.	5.8	105
189	Increasing Rates of Gastroenteritis Hospital Discharges in US Adults and the Contribution of Norovirus, 1996–2007. Clinical Infectious Diseases, 2011, 52, 466-474.	5.8	181
190	Direct and Indirect Effects of Rotavirus Vaccination Upon Childhood Hospitalizations in 3 US Counties, 2006–2009. Clinical Infectious Diseases, 2011, 53, 245-253.	5.8	163
191	Air Sickness: Vomiting and Environmental Transmission of Norovirus on Aircraft. Clinical Infectious Diseases, 2011, 53, 521-522.	5.8	12
192	Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence. Journal of the Royal Society Interface, 2011, 8, 1584-1593.	3.4	73
193	Infant Rotavirus Vaccination May Provide Indirect Protection to Older Children and Adults in the United States. Journal of Infectious Diseases, 2011, 204, 980-986.	4.0	178
194	Patterns of Self-reported Behaviour Change Associated with Receiving Voluntary Counselling and Testing in a Longitudinal Study from Manicaland, Zimbabwe. AIDS and Behavior, 2010, 14, 708-715.	2.7	50
195	SPATIOTEMPORAL DYNAMICS OF ROTAVIRUS DISEASE IN EUROPE. Pediatric Infectious Disease Journal, 2010, 29, 566-568.	2.0	12
196	HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review. International Journal of Epidemiology, 2010, 39, 1311-1323.	1.9	121
197	Community Incidence of Norovirus-associated Infectious Intestinal Disease in England: Improved Estimates Using Viral Load for Norovirus Diagnosis. American Journal of Epidemiology, 2010, 171, 1014-1022.	3.4	126
198	Asymptomatic Rotavirus Infections in England: Prevalence, Characteristics, and Risk Factors. American Journal of Epidemiology, 2010, 171, 1023-1030.	3.4	44

#	Article	IF	CITATIONS
199	Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine, 2010, 28, 3118-3126.	3.8	58
200	Host, Weather and Virological Factors Drive Norovirus Epidemiology: Time-Series Analysis of Laboratory Surveillance Data in England and Wales. PLoS ONE, 2009, 4, e6671.	2.5	120
201	Hospital Admissions Due to Norovirus in Adult and Elderly Patients in England. Clinical Infectious Diseases, 2009, 49, 1890-1892.	5.8	41
202	Diagnosing rotavirus A associated IID: Using ELISA to identify a cut-off for real time RT-PCR. Journal of Clinical Virology, 2009, 44, 242-245.	3.1	71
203	The Evolution of Norovirus, the "Gastric Flu― PLoS Medicine, 2008, 5, e42.	8.4	50
204	Estimating Incidence from Prevalence in Generalised HIV Epidemics: Methods and Validation. PLoS Medicine, 2008, 5, e80.	8.4	117
205	HIV incidence in 3 years of follow-up of a Zimbabwe cohort—1998–2000 to 2001–03: contributions of proximate and underlying determinants to transmission. International Journal of Epidemiology, 2008, 37, 88-105.	1.9	42
206	Deaths from Norovirus among the Elderly, England and Wales. Emerging Infectious Diseases, 2008, 14, 1546-1552.	4.3	180
207	When Did HIV Incidence Peak in Harare, Zimbabwe? Back-Calculation from Mortality Statistics. PLoS ONE, 2008, 3, e1711.	2.5	20
208	Critique of early models of the demographic impact of HIV/AIDS in sub-Saharan Africa based on contemporary empirical data from Zimbabwe. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14586-14591.	7.1	32
209	Voluntary counselling and testing: uptake, impact on sexual behaviour, and HIV incidence in a rural Zimbabwean cohort. Aids, 2007, 21, 851-860.	2.2	179
210	Poorer health and nutritional outcomes in orphans and vulnerable young children not explained by greater exposure to extreme poverty in Zimbabwe. Tropical Medicine and International Health, 2007, 12, 584-593.	2.3	51
211	Age at First Sex and HIV Infection in Rural Zimbabwe. Studies in Family Planning, 2007, 38, 1-10.	1.8	63
212	HIV-contaminated syringes are not evidence of transmission. Aids, 2006, 20, 1905.	2.2	4
213	Creating and Validating an Algorithm to Measure AIDS Mortality in the Adult Population using Verbal Autopsy. PLoS Medicine, 2006, 3, e312.	8.4	78
214	Noroviruses: Simple Detection for Complex Epidemiology. Clinical Infectious Diseases, 2006, 42, 970-971.	5.8	8
215	Rising incidence and prevalence of orphanhood in Manicaland, Zimbabwe, 1998 to 2003. Aids, 2005, 19, 717-725.	2.2	35
216	Disease Risks from Foods, England and Wales, 1996–2000. Emerging Infectious Diseases, 2005, 11, 365-372.	4.3	232

#	Article	IF	CITATIONS
217	Authors' Reply: Don't Let the Hypothesis Slip. PLoS Medicine, 2005, 2, e147.	8.4	1
218	Individual Level Injection History: A Lack of Association with HIV Incidence in Rural Zimbabwe. PLoS Medicine, 2005, 2, e37.	8.4	32
219	Epidemiology and Cost of Nosocomial Gastroenteritis, Avon, England, 2002–2003. Emerging Infectious Diseases, 2004, 10, 1827-1834.	4.3	194
220	Diversity of Noroviruses Cocirculating in the North of England from 1998 to 2001. Journal of Clinical Microbiology, 2004, 42, 1396-1401.	3.9	61
221	Clinical Manifestation of Norovirus Gastroenteritis in Health Care Settings. Clinical Infectious Diseases, 2004, 39, 318-324.	5.8	259
222	Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet, The, 2004, 363, 682-688.	13.7	458
223	Epidemiologists: clinging to coat-tails or donning them?. International Journal of Epidemiology, 2003, 32, 880-881.	1.9	1
224	Viral Gastroenteritis Outbreaks in Europe, 1995–2000. Emerging Infectious Diseases, 2003, 9, 90-96.	4.3	279
225	Two Epidemiologic Patterns of <i>Norovirus</i> Outbreaks: Surveillance in England and Wales, 1992–2000. Emerging Infectious Diseases, 2003, 9, 71-77.	4.3	204
226	Early Identification of Common-Source Foodborne Virus Outbreaks in Europe. Emerging Infectious Diseases, 2003, 9, 1136-1142.	4.3	114
227	Genome-wide linkage analysis of inherited hydrocephalus in the H-Tx rat. Mammalian Genome, 2001, 12, 22-26.	2.2	29
228	Association Between Rotavirus Vaccination and Antibiotic Prescribing among Commercially Insured US Children, 2007-2018. Open Forum Infectious Diseases, 0, , .	0.9	3